Emergent BioSolutions Sees Q2 Sales $170.000M-$185.000M vs $186.000M Est
Benzinga Newsdesk 6 months ago
NewsGuidance
Emergent BioSolutions (NYSE:EBS) sees Q2 sales of $170.000 million-$185.000 million vs $186.000 million analyst estimate.
Emergent BioSolutions (NYSE:EBS) sees Q2 sales of $170.000 million-$185.000 million vs $186.000 million analyst estimate.